0000899243-22-011698.txt : 20220321 0000899243-22-011698.hdr.sgml : 20220321 20220321160511 ACCESSION NUMBER: 0000899243-22-011698 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220307 FILED AS OF DATE: 20220321 DATE AS OF CHANGE: 20220321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Werner Milton H. CENTRAL INDEX KEY: 0001827621 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39676 FILM NUMBER: 22755759 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc. CENTRAL INDEX KEY: 0001750149 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 678-392-3419 MAIL ADDRESS: STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900 CITY: ATLANTA STATE: GA ZIP: 30339 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-07 0 0001750149 Inhibikase Therapeutics, Inc. IKT 0001827621 Werner Milton H. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 1 1 1 0 President and CEO Common Stock 5315433 D Stock Option (right to buy) 1.07 2022-03-07 4 A 0 125000 0.00 A 2029-03-07 Common Stock 125000 125000 D One-third of the options will vest and become exercisable on 3/7/2023, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of April 2023, subject to continued employment through each such vesting date. The original Form 4, filed on March 9, 2022, is being amended by this Form 4 amendment solely to correct an error that misreported that the 24 equal monthly installments mentioned in footnote 1 would begin on the first day of April 2024, rather than the first day of April 2023 as intended. /s/ Milton H. Werner 2022-03-21